Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alaric DeArment

Reporter

Alaric has covered health care and the biopharma industry for over 12 years. He started out covering retail pharmacy for Drug Store News and shifted to writing for the pharma audience at BioPharm Insight, where highlights of his coverage included breaking stories about the early growing pains of CAR-T cell therapy development. Most recently he covered the biopharma beat at MedCity News. His professional interests include cell and gene therapies, hematology-oncology and the intersection of biopharma with artificial intelligence and machine learning. A native of Seattle, he holds a bachelor degree in journalism from Ball State University and also lived in China for three years. He is currently based in Brooklyn. Outside of work, Alaric’s interests include reading, coin collecting, travel and languages.

Latest From Alaric DeArment

Proteome-Focused ProFound Emerges From Flagship Pioneering

The company says its platform technology has uncovered “tens of thousands” of previously undiscovered proteins.

Companies Financing

Could CAR-Ts Roll Into The Community Setting?

While CAR-Ts have yet to trickle down into community oncology, research focused on the CAR-T patient journey also surveyed community practices on CAR-T outside the traditional academic space. 

Cancer ImmunoOncology

SpringWorks Targets Rare Tumors, But Myeloma Is The Mother Lode

The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.

Cancer Clinical Trials

Foghorn’s AML/MDS Program Likely Still A Go Despite Partial Hold

The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.

Clinical Trials Safety

Ocuphire Chalks Up Another Phase III Success For Nyxol

The company announced positive topline results for the drug in night vision disturbance and may conduct another pivotal trial as it focuses on myadriasis and presbyopia.

Business Strategies Ophthalmic

Moderna Spotlights Lung Delivery As One Of Its mRNA 'Dreams'

The company’s emphasis on artificial intelligence has played a leading role in development of lipid nanoparticles enabling delivery of mRNA to lung tissue under a partnership with Vertex.

Artificial Intelligence Business Strategies
See All
UsernamePublicRestriction

Register